Jakafi (Ruxolitinib)
Get Latest Price
Ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an ...Molar mass: 306.37 g/molBioavailability: 95%Formula: C17H18N6Synonyms: INCB018424, INC424PDB ligand: RXT (PDBe, RCSB PDB)Trade name: Jakafi, Jakavi
View Complete Details
Get Latest PriceRequest a quote
Product Details
Company Details
Product Description
Ruxolitinib is a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an ...Molar mass: 306.37 g/molBioavailability: 95%Formula: C17H18N6Synonyms: INCB018424, INC424PDB ligand: RXT (PDBe, RCSB PDB)Trade name: Jakafi, Jakavi
Additional Information
Payment Terms | L/C (Letter of Credit),T/T (Bank Transfer),D/P,D/A |
Interested in this product?Get Latest Price from the seller
Contact Seller
About the Company
Year of Establishment1980
Legal Status of FirmPartnership Firm
Nature of BusinessWholesale Supplier
Number of Employees26 To 50 People
Annual TurnoverRs. 1 - 2 Crore
IndiaMART Member SinceAug 2017
Aventis Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Committed to 'Serve Health Care Needs Worldwide', we produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market we are present in. We clearly understand our customer's needs and use cutting edge technology to present innovative solutions. Our business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
Seller Contact Details
Patel Murat
28- A, Block Ab, Safdarjung Enclave, Safdarjung Enclave New Delhi - 110029, India
Get DirectionsView Mobile No.
Send SMS
Send Email